collection
MENU ▼
Read by QxMD icon Read
search

UBC Endocrinology Professor Rounds

shared collection
92 papers 25 to 100 followers Weekly Professor Rounds at the UBC Division of Endocrinology
By Ehud Ur Professor and Head, Endocrinology, UBC, Vancouver
https://www.readbyqxmd.com/read/27811940/the-endocrine-manifestations-of-anorexia-nervosa-mechanisms-and-management
#1
REVIEW
Melanie Schorr, Karen K Miller
Anorexia nervosa is a psychiatric disorder characterized by altered body image, persistent food restriction and low body weight, and is associated with global endocrine dysregulation in both adolescent girls and women. Dysfunction of the hypothalamic-pituitary axis includes hypogonadotropic hypogonadism with relative oestrogen and androgen deficiency, growth hormone resistance, hypercortisolaemia, non-thyroidal illness syndrome, hyponatraemia and hypooxytocinaemia. Serum levels of leptin, an anorexigenic adipokine, are suppressed and levels of ghrelin, an orexigenic gut peptide, are elevated in women with anorexia nervosa; however, levels of peptide YY, an anorexigenic gut peptide, are paradoxically elevated...
November 4, 2016: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/27654602/effect-of-wearable-technology-combined-with-a-lifestyle-intervention-on-long-term-weight-loss-the-idea-randomized-clinical-trial
#2
John M Jakicic, Kelliann K Davis, Renee J Rogers, Wendy C King, Marsha D Marcus, Diane Helsel, Amy D Rickman, Abdus S Wahed, Steven H Belle
Importance: Effective long-term treatments are needed to address the obesity epidemic. Numerous wearable technologies specific to physical activity and diet are available, but it is unclear if these are effective at improving weight loss. Objective: To test the hypothesis that, compared with a standard behavioral weight loss intervention (standard intervention), a technology-enhanced weight loss intervention (enhanced intervention) would result in greater weight loss...
September 20, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27700539/is-a-normal-tsh-synonymous-with-euthyroidism-in-levothyroxine-monotherapy
#3
Sarah J Peterson, Elizabeth A McAninch, Antonio C Bianco
CONTEXT: Levothyroxine (LT4) monotherapy is the standard of care for hypothyroidism. OBJECTIVE: To determine whether LT4 at doses that normalize the serum TSH is associated with normal markers of thyroid status. DESIGN: Cross-sectional data from the US National Health and Nutrition Examination Survey (2001-2012) was used to evaluate 52 clinical parameters. LT4-users were compared to healthy controls and controls matched for age, sex, race, and serum TSH...
October 4, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27633186/semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes
#4
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren, Vincent Woo, Oluf Hansen, Anders G Holst, Jonas Pettersson, Tina Vilsbøll
Background Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown. Methods We randomly assigned 3297 patients with type 2 diabetes who were on a standard-care regimen to receive once-weekly semaglutide (0.5 mg or 1.0 mg) or placebo for 104 weeks...
September 15, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27643842/diagnosis-of-recurrence-in-cushing-s-disease-american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-disease-state-clinical-review
#5
Maria Fleseriu, Amir H Hamrahian, Andrew R Hoffman, Daniel F Kelly, Laurence Katznelson
Recurrence of hypercortisolemia after initial treatment of Cushing's disease (CD) is more common than previously thought, with a third of patients suffering a recurrence over their lifetime. Awareness of this high rate and delayed timeline (sometimes decades) of potential recurrence is critical and patients with CD should be monitored at regular intervals throughout their lives. In this manuscript, we review the complex evaluation needed for defining CD remission versus persistent disease after surgery, and focus on challenges in diagnosing early recurrent hypercortisolemia...
September 19, 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27662440/the-desmopressin-test-predicts-better-than-basal-cortisol-the-long-term-surgical-outcome-of-cushing-s-disease
#6
D A Vassiliadi, M Balomenaki, A Asimakopoulou, E Botoula, M Tzanela, S Tsagarakis
CONTEXT: Cushing's disease (CD) has a significant relapse rate after successful transsphenoidal surgery (TSS). Many CD patients respond aberrantly to desmopressin testing (DT). Disappearance of this response post-surgery may suggest complete removal of abnormal corticotrophs and lower possibility of recurrence. OBJECTIVE: The utility of post-operative DT to predict long-term outcome compared to the widely used post-operative cortisol (Cort) level. DESIGN: Retrospective analysis...
September 23, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27009625/effects-of-sodium-glucose-cotransporter-2-inhibitors-on-cardiovascular-events-death-and-major-safety-outcomes-in-adults-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#7
Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal
BACKGROUND: In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to increase LDL cholesterol and the incidence of urogenital infections. Protection against cardiovascular events has also been reported, as have possible increased risks of adverse outcomes such as ketoacidosis and bone fracture. We aimed to establish the effects of SGLT2 inhibitors on cardiovascular events, death, and safety outcomes in adults with type 2 diabetes, both overall and separately for individual drugs...
May 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/26831302/glp-1-receptors-exist-in-the-parietal-cortex-hypothalamus-and-medulla-of-human-brains-and-the-glp-1-analogue-liraglutide-alters-brain-activity-related-to-highly-desirable-food-cues-in-individuals-with-diabetes-a-crossover-randomised-placebo-controlled-trial
#8
Olivia M Farr, Michail Sofopoulos, Michael A Tsoukas, Fadime Dincer, Bindiya Thakkar, Ayse Sahin-Efe, Andreas Filippaios, Jennifer Bowers, Alexandra Srnka, Anna Gavrieli, Byung-Joon Ko, Chrysoula Liakou, Nickole Kanyuch, Sofia Tseleni-Balafouta, Christos S Mantzoros
AIMS/HYPOTHESIS: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue that has been demonstrated to successfully treat diabetes and promote weight loss. The mechanisms by which liraglutide confers weight loss remain to be fully clarified. Thus, we investigated whether GLP-1 receptors are expressed in human brains and whether liraglutide administration affects neural responses to food cues in diabetic individuals (primary outcome). METHODS: In 22 consecutively studied human brains, expression of GLP-1 receptors in the hypothalamus, medulla oblongata and parietal cortex was examined using immunohistochemistry...
May 2016: Diabetologia
https://www.readbyqxmd.com/read/26786291/sulfonylurea-use-and-the-risk-of-hospital-readmission-in-patients-with-type-2-diabetes
#9
Pamela C Heaton, Vibha C A Desai, Christina M L Kelton, Swapnil N Rajpathak
BACKGROUND: Hospital inpatient care for patients with diabetes was estimated to cost $76 billion in 2012. Substantial expense resulted from those patients having multiple hospitalizations. The objective was to compare the risk for diabetes-related hospital readmission in patients with type 2 diabetes treated with sulfonylureas (SUs) compared to those treated with other oral antihyperglycemic agents (AHAs). METHODS: A retrospective cohort analysis was conducted using two-year panels, from 1999 to 2010, from the Medical Expenditure Panel Survey...
2016: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/27032548/pharmacologic-management-of-type-2-diabetes-2016-interim-update
#10
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Canadian Journal of Diabetes
https://www.readbyqxmd.com/read/27035920/the-prevalence-of-diabetes-and-prediabetes-in-the-adult-population-of-jeddah-saudi-arabia-a-community-based-survey
#11
Suhad M Bahijri, Hanan A Jambi, Rajaa M Al Raddadi, Gordon Ferns, Jaakko Tuomilehto
BACKGROUND: Type 2 (T2DM) is believed to be common in Saudi Arabia, but data are limited. In this population survey, we determined the prevalence of T2DM and prediabetes. MATERIALS AND METHODS: A representative sample among residents aged ≥ 18 years of the city of Jeddah was obtained comprising both Saudi and non-Saudi families (N = 1420). Data on dietary, clinical and socio-demographic characteristics were collected and anthropometric measurements taken. Fasting plasma glucose and glycated hemoglobin (HbA1c) were used to diagnose diabetes and prediabetes employing American Diabetes Association criteria...
2016: PloS One
https://www.readbyqxmd.com/read/26861926/metabolic-impact-of-nonalcoholic-steatohepatitis-in-obese-patients-with-type-2-diabetes
#12
Romina Lomonaco, Fernando Bril, Paola Portillo-Sanchez, Carolina Ortiz-Lopez, Beverly Orsak, Diane Biernacki, Margaret Lo, Amitabh Suman, Michelle H Weber, Kenneth Cusi
OBJECTIVE: Nonalcoholic steatohepatitis (NASH) is increasingly common in obese patients. However, its metabolic consequences in patients with type 2 diabetes mellitus (T2DM) are unknown. RESEARCH DESIGN AND METHODS: We studied 154 obese patients divided in four groups: 1) control (no T2DM or NAFLD), 2) T2DM without NAFLD, 3) T2DM with isolated steatosis, and 4) T2DM with NASH. We evaluated intrahepatic triglycerides by proton MRS ((1)H-MRS) and assessed insulin secretion/resistance during an oral glucose tolerance test and a euglycemic-hyperinsulinemic clamp with glucose turnover measurements...
April 2016: Diabetes Care
https://www.readbyqxmd.com/read/26889940/agrp-neuron-specific-deletion-of-glucocorticoid-receptor-leads-to-increased-energy-expenditure-and-decreased-body-weight-in-female-mice-on-a-high-fat-diet
#13
Miyuki Shibata, Ryoichi Banno, Mariko Sugiyama, Takashi Tominaga, Takeshi Onoue, Taku Tsunekawa, Yoshinori Azuma, Daisuke Hagiwara, Wenjun Lu, Yoshihiro Ito, Motomitsu Goto, Hidetaka Suga, Yoshihisa Sugimura, Yutaka Oiso, Hiroshi Arima
Agouti-related protein (AgRP) expressed in the arcuate nucleus is a potent orexigenic neuropeptide, which increases food intake and reduces energy expenditure resulting in increases in body weight (BW). Glucocorticoids, key hormones that regulate energy balance, have been shown in rodents to regulate the expression of AgRP. In this study, we generated AgRP-specific glucocorticoid receptor (GR)-deficient (knockout [KO]) mice. Female and male KO mice on a high-fat diet (HFD) showed decreases in BW at the age of 6 weeks compared with wild-type mice, and the differences remained significant until 16 weeks old...
April 2016: Endocrinology
https://www.readbyqxmd.com/read/26817691/early-cardiovascular-events-in-women-with-a-history-of-gestational-diabetes-mellitus
#14
Karine Goueslard, Jonathan Cottenet, Anne-Sophie Mariet, Maurice Giroud, Yves Cottin, Jean-Michel Petit, Catherine Quantin
BACKGROUND: The effect of gestational diabetes mellitus (GDM) on cardiovascular diseases (CVD) is not assessed within the first 10 years postpartum, regardless of subsequent diabetes. The aim of this study was to determine the risk of CVD events related to GDM within 7 years of postpartum. METHODS: This nationwide population-based study of deliveries in 2007 and 2008 with a follow-up of 7 years was based on data from the French medico-administrative database. Two groups were formed: women with a history of GDM and women without GDM or previous diabetes...
2016: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/26886521/effects-of-testosterone-treatment-in-older-men
#15
RANDOMIZED CONTROLLED TRIAL
Peter J Snyder, Shalender Bhasin, Glenn R Cunningham, Alvin M Matsumoto, Alisa J Stephens-Shields, Jane A Cauley, Thomas M Gill, Elizabeth Barrett-Connor, Ronald S Swerdloff, Christina Wang, Kristine E Ensrud, Cora E Lewis, John T Farrar, David Cella, Raymond C Rosen, Marco Pahor, Jill P Crandall, Mark E Molitch, Denise Cifelli, Darlene Dougar, Laura Fluharty, Susan M Resnick, Thomas W Storer, Stephen Anton, Shehzad Basaria, Susan J Diem, Xiaoling Hou, Emile R Mohler, J Kellogg Parsons, Nanette K Wenger, Bret Zeldow, J Richard Landis, Susan S Ellenberg
BACKGROUND: Serum testosterone concentrations decrease as men age, but benefits of raising testosterone levels in older men have not been established. METHODS: We assigned 790 men 65 years of age or older with a serum testosterone concentration of less than 275 ng per deciliter and symptoms suggesting hypoandrogenism to receive either testosterone gel or placebo gel for 1 year. Each man participated in one or more of three trials--the Sexual Function Trial, the Physical Function Trial, and the Vitality Trial...
February 18, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/26891118/iodine-supplementation-of-mildly-iodine-deficient-adults-lowers-thyroglobulin-a-randomized-controlled-trial
#16
Zheng Feei Ma, Bernard J Venn, Patrick J Manning, Claire M Cameron, Sheila A Skeaff
This study demonstrates that thyroglobulin decreases when iodine status improves, demonstrating that thyroglobulin is a useful index of iodine status in a group of adults.
April 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/26851767/serum-thyroglobulin-as-a-biomarker-of-iodine-deficiency-in-adult-populations
#17
Anne Krejbjerg, Lena Bjergved, Inge Bülow Pedersen, Allan Carlé, Nils Knudsen, Hans Perrild, Lars Ovesen, Lone Banke Rasmussen, Peter Laurberg
OBJECTIVE: To clarify which factors may influence the serum Tg level in an adult population and how this may affect Tg as a biomarker of iodine deficiency (ID). DESIGN AND METHODS: Two identical cross-sectional studies were performed before (C1a: 1997-98, n = 4649) and after (C2: 2004-05, n = 3570) the Danish mandatory iodine fortification (IF) of salt (2000). Additionally, a follow-up study of C1a was performed after IF (C1b: 2008-10, n = 2465). The studies took place in two regions with mild (Copenhagen) and moderate (Aalborg) ID before IF...
September 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/26863422/predicting-the-risk-of-recurrence-before-the-start-of-antithyroid-drug-therapy-in-patients-with-graves-hyperthyroidism
#18
Xander G Vos, Erik Endert, A H Zwinderman, Jan G P Tijssen, Wilmar M Wiersinga
Genotyping increases the accuracy of a clinical score (based on pretreatment age, goiter size, FT4, TBII) for predicting recurrence of Graves' hyperthyroidism after a course of antithyroid drugs: a prospective study.
April 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/26822326/nine-year-effects-of-3-7-years-of-intensive-glycemic-control-on-cardiovascular-outcomes
#19
(no author information available yet)
OBJECTIVE: In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, ∼4 years of intensive versus standard glycemic control in participants with type 2 diabetes and other cardiovascular risk factors had a neutral effect on the composite cardiovascular outcome, increased cardiovascular and total mortality, and reduced nonfatal myocardial infarction. Effects of the intervention during prolonged follow-up were analyzed. RESEARCH DESIGN AND METHODS: All surviving ACCORD participants were invited to participate in the ACCORD Follow-on (ACCORDION) study, during which participants were treated according to their health care provider's judgment...
May 2016: Diabetes Care
https://www.readbyqxmd.com/read/26815881/antithyroid-drug-side-effects-in-the-population-and-in-pregnancy
#20
Stine Linding Andersen, Jørn Olsen, Peter Laurberg
In a Danish population study using health registers, agranulocytosis caused by antithyroid drugs was 4 times more frequent than liver failure. Both were very rare in pregnancy, where birth defects were the dominant side effect.
April 2016: Journal of Clinical Endocrinology and Metabolism
label_collection
label_collection
1722
1
2
2016-01-30 17:36:28
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"